Lumiracoxib.
Lyseng-Williamson
Katherine A
KA
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Curran
Monique P
MP
D000284:Administration, Oral; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D004008:Diclofenac / Q000031:analogs & derivatives; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D015394:Molecular Structure; D009520:New Zealand; D009930:Organic Chemicals / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy; D010098:Oxycodone / Q000494:pharmacology / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D009626:Terminology as Topic; D014944:World Health Organization
D016861:Cyclooxygenase Inhibitors; D009930:Organic Chemicals; D011720:Pyrazoles; D013449:Sulfonamides; D004008:Diclofenac; D010098:Oxycodone; D000068579:Celecoxib; C473384:lumiracoxib